about
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responsesSustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAbMonoclonal antibodies combined with adenovirus-vectored interferon significantly extend the treatment window in Ebola virus-infected guinea pigsSpread of ZIKV and YFV to China: Potential ImplicationsMore Challenges From Ebola: Infection of the Central Nervous SystemCharacterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in MiceEstablishment and characterization of a lethal mouse model for the Angola strain of Marburg virusDelivering Prolonged Intensive Care to a Non-human Primate: A High Fidelity Animal Model of Critical Illness.Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over timePost-exposure therapy of filovirus infections.Reversion of advanced Ebola virus disease in nonhuman primates with ZMappStructures of protective antibodies reveal sites of vulnerability on Ebola virus.The multiple roles of sGP in Ebola pathogenesisEbola virus transmission in guinea pigs.Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infectionProgression of Ebola Therapeutics During the 2014-2015 Outbreak.A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola InfectionAdenovirus-Vectored Vaccine Provides Postexposure Protection to Ebola Virus-Infected Nonhuman Primates.Ebola viral load at diagnosis associates with patient outcome and outbreak evolution.Development and Characterization of a Guinea Pig-Adapted Sudan Virus.Can Ebola virus become endemic in the human population?Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection.Potent neutralizing monoclonal antibodies against Ebola virus infectionAntibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding SiteAntibody therapy for Ebola: is the tide turning around?Antibody therapeutics for Ebola virus disease.Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection.Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primatesFerrets Infected with Bundibugyo Virus or Ebola Virus Recapitulate Important Aspects of Human Filovirus Disease.The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.Ebola virus infection kinetics in chimeric mice reveal a key role of T cells as barriers for virus dissemination.Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.Characterization of host immune responses in Ebola virus infections.Development of experimental and early investigational drugs for the treatment of Ebola virus infections.Clinical Evaluation of Ebola Virus Disease Therapeutics.Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus.An Adenovirus Vaccine Expressing Ebola Virus Variant Makona Glycoprotein Is Efficacious in Guinea Pigs and Nonhuman Primates.The emergence of antibody therapies for Ebola.Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo.
P50
Q21562420-3758C9D1-DC5C-48E8-BA0E-487D8EAA9138Q24594601-B42FED10-ECF8-4C08-A43B-33490BC53CF0Q24604416-FF3B78FD-F1AF-42C2-9017-380B59D5E76EQ24657479-4EC62FD1-17A7-4E92-B83E-E81BA589A7F1Q28390883-4DC5233C-6B1F-44EE-9275-B3C8BC36FB1DQ30375073-B0240C80-6608-47AD-9A49-AE68F0B129FCQ33417197-3CCA39D2-0704-4286-A64B-2D810DACD339Q33682491-1250AC95-0C42-4514-BDAC-825E09096F83Q33794406-73BA983B-69F5-4629-B5FD-B2383EECD955Q34040813-F8113FDD-B489-4314-9C57-00AE43DD2621Q34426585-8FAFC4E1-01FB-48AB-8C51-8874CD48105DQ34661120-624553B1-A9B1-44A3-A57A-3F36E3DC4AA6Q34869463-5E9758AE-0C0B-4087-99D9-27531CA11C9AQ34991054-A2C6F684-BCB6-45D3-B689-C078CE98B94DQ35842390-C6715A6B-F0EC-4539-9307-876A45B69360Q35895955-D319CB82-B9B9-43CF-998A-36BE3638A6DDQ35917501-01C46A07-140B-4C44-99ED-853D7FD3AAF1Q36043199-76A381F1-F4ED-462F-949E-71DDFD1A48D9Q36335863-552E7B14-E1CD-44AE-9121-21B518CCE198Q36433906-9E6B96F2-2FE8-4A83-B048-85D01A5DFEB0Q36447887-284A98BB-AED7-47BC-AAC8-5B2738CF56CEQ36789989-63C9EEE4-B1E5-485D-B85B-0B90C8F7002BQ36903111-833B7070-F6DC-428B-8097-611C469C5520Q36913606-6223D5FF-0269-46F3-9F41-78DCEAB43769Q36977744-C0BD1FAD-BD69-4556-B206-BAE78565AD25Q36994087-CB2469B5-F374-45B2-A1AC-D3CDBC457BF8Q37203877-18E322C0-5382-40DE-B855-B169771F0CD4Q37213207-8787CD66-02ED-42F6-A26E-D29352EC308AQ37300391-B7F47F0F-8533-4965-B74E-F94EE4F2B628Q37448307-AD57B167-829F-4122-B4B4-0F825CEE8667Q37631492-30F85D76-568C-4385-8597-DA9098CCAC25Q37678872-9E777537-0483-4F7C-95A8-8E2AEBC879E6Q37738447-3B31833A-4215-4A26-ADAA-A2BBCD0A8033Q38205274-7CB7D26E-2C96-45BE-A3DD-71171A8D8A13Q38524949-E06C2778-A4AB-4DAA-92DB-ECB0DCE7F942Q38617605-91779203-0FE0-4459-90D2-E2F5429A85BAQ38782718-14B35D58-727D-448C-8E49-CA7E58CB03FCQ38834286-918DBE49-54B8-4AD0-B974-5F7618A7B38DQ38912605-9BA78F17-C0FA-4D77-9FA1-6725F1DB4EEAQ39138259-7C68C639-0A52-4C1A-AD63-0DC73FAF56DC
P50
name
Xiangguo Qiu
@ast
Xiangguo Qiu
@en
Xiangguo Qiu
@nl
type
label
Xiangguo Qiu
@ast
Xiangguo Qiu
@en
Xiangguo Qiu
@nl
prefLabel
Xiangguo Qiu
@ast
Xiangguo Qiu
@en
Xiangguo Qiu
@nl